Skip to main content

Life Sciences is now live. See how →

Patent Examiner Sudhakar Katakam

Art Unit 1658 · Peptide & Protein Therapeutics · Tech Center 1600 · 336 applications filed 2021–2026

⚑ Hard · harder than 74% of examiners● Free examiner data

Sudhakar Katakam is a USPTO patent examiner in Art Unit 1658 (Peptide & Protein Therapeutics) with 336 applications from filing years 2021–2026. Examiner Katakam's allowance rate is 69.5%, below the 81.9% USPTO average for applications filed in the same years. The examiner ranks harder than 74% of examiners. In 2021, decided applications with an examiner interview were allowed 62.5 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 74% of examiners
Easier74th percentileHarder
Allowance rate vs peers
Examiner Katakam69.5%
Art Unit 165854.0%
USPTO average81.9%
Allowance rate
69.5%
▼ USPTO avg 81.9%
Applications
336
filing years 2021–2026
First-action allowance
6.0%
patented with no rejection
Abandoned
18.1%
share of applications
Avg office actions
1.4
USPTO avg 1.4
Days to first OA
748
▲ USPTO 631
RCE rate
24.4%
USPTO 20.5%
Interview rate
37.5%
USPTO 28.3%

Examiner details

  • Art unit1658 · Peptide & Protein Therapeutics
  • Title / gradePrimary Patent Examiner · GS-14
  • Service20 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsKATAKAM, SUDHAKAR
Full signatory authority

Examiner Katakam can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions530 · Chemistry: Natural Resins, Peptides or Proteins & Lignins424 · Drug, Bio-Affecting & Body Treating Compositions

How to improve your odds with Examiner Katakam

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 39.7 to 66.7 points.
  • Plan for the timeline. First office action averages 748 days vs the 631-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (191), and applicants overcame it 53.6% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 21.8 to 43.3 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty37 issued · 85.2% overcome
§103 Obviousness191 issued · 53.6% overcome
§112 Definiteness & disclosure89 issued · 77.6% overcome
How applicants traverse §103 rejections🔒 Members

Of the 42 winning responses to Examiner Katakam's §103 rejections that Boundly has classified, 35 (83%) amended the claims and argued, 4 argued without amending, and 3 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Katakam?

Draft your response with Examiner Katakam's record and Art Unit 1658's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Katakam.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202312.1%85.7%63.9%+21.8pp
202231.6%93.3%50.0%+43.3pp
202140.9%91.4%62.3%+29.1pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/244800Therapeutic Agents for Treatment of Coronavirus InfectionAbandoned0🔒 View
18/015927Novel Peptoid Compounds That Bind to Cell Receptor ACE2 and Prevent Virus Entry into CellsPatented1🔒 View
19/329353Cyclic Cell Penetrating Peptides and Methods of Making and Using ThereofPatented1🔒 View
18/451003Polypeptides Including a Beta-Tricalcium Phosphate-Binding Sequence and Uses ThereofPatented1🔒 View
See all 336 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1658 technology

Antimicrobial & antiviral peptidesAnticancer peptides & proteinsDiabetes & obesity peptidesPeptide compounds & synthesisTop CPC A61K · C07K · C12N
About this examiner. Sudhakar Katakam examines in Art Unit 1658 (Peptide & Protein Therapeutics, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Sudhakar Katakam's allowance rate?
Examiner Katakam's allowance rate is 69.5%, compared with 81.9% across the USPTO and 54.0% in Art Unit 1658 for applications filed in the same years. That rate ranks Examiner Katakam harder than 74% of examiners.
Is Examiner Katakam a hard examiner?
Somewhat. Examiner Katakam ranks harder than 74% of examiners, in the 74th difficulty percentile (hard). Examiner Katakam has a 69.5% allowance rate versus 81.9% across the USPTO and 54.0% in Art Unit 1658, 1.4 office actions per application versus 1.4, and an RCE rate of 24.4% versus 20.5% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Katakam?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 39.7 to 66.7 percentage points. In 2021, 93.8% of decided applications with an interview were allowed, versus 31.3% of those without.
What is Examiner Katakam's most common rejection?
§103 obviousness, issued 191 times in the data. Applicants overcame it 53.6% of the time. Of the 42 winning responses Boundly has classified, 35 amended the claims and argued.
Is an RCE worth filing with Examiner Katakam?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 3 measured years, by 21.8 to 43.3 percentage points. In 2021, 91.4% of decided applications with an RCE were allowed, versus 62.3% of those without one.
How long until the first office action from Examiner Katakam?
About 748 days on average, versus 631 days across the USPTO for applications filed in the same years.
How do I contact Examiner Sudhakar Katakam?
Examiner Katakam can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Katakam's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Sudhakar Katakam, or see an error? Request a correction.